The aim of this study was to examine the relationship between different preincubation periods of oocytes and the outcome of intracytoplasmic sperm injection (ICSI). We analysed retrospectively 95 ICSI treatment cycles performed to alleviate severe male-factor infertility. Oocyte collection was performed approximately 36 h after human chorionic gonadotrophin administration. The cumulus-corona-oocyte complexes obtained were incubated until the moment of ICSI. Fertilization, embryo development and implantation rates were analysed in four groups, which were divided according to the time lapse between oocyte retrieval and ICSI: group I, < or =3 h (18 cycles); group II, >3-< or =6 h (52 cycles); group III, >6-< or =9 h (14 cycles); and group IV, >9-< or =12 h (11 cycles). Immediately before ICSI the cumulus and corona cells were removed from the oocytes. A total of 723 metaphase II oocytes were injected: 126 from group I, 380 from group II, 126 from group III and 91 from group IV. The fertilization rates obtained were 52.3, 66.8, 65.1 and 69.2% respectively [P < 0.05 (using the chi2 test) between group I and groups II, III and IV]. Cleavage rates were similar in all groups (68.1, 69.7, 79.2 and 79.3% respectively), but the proportion of good quality embryos (< or =20% fragmentation) was significantly lower (P < 0.05) in group I (24.2%) compared with groups II (39.8%) and IV (39.6%). However, no statistically significant differences were observed between the four groups with regard to implantation rates (11.7, 13.2, 10.4 and 20.4% respectively). The results suggest that a preincubation period between oocyte retrieval and ICSI can improve the fertilization rate and embryo quality. This period might be necessary for some oocytes to reach full cytoplasmic maturity, leading to a higher activation rate upon microinjection.
BACKGROUNDRecent advancement of minimum volume vitrification methods has resulted in a dramatic increase in the efficiency of the process. The aim of this study was to estimate the cumulative reproductive outcome of a cohort of infertile couples undergoing ICSI and oocyte vitrification in restrictive legal conditions, where only a limited number of oocytes could be inseminated per cycle and embryo selection and cryopreservation were forbidden.METHODSIn this prospective longitudinal cohort study, the cumulative ongoing pregnancy rates obtained by the insemination of fresh and vitrified oocytes from the same cohort were calculated as primary outcome measures. Moreover, the effect of basal and cycle characteristics on clinical outcomes were assessed.RESULTSBetween September 2008 and May 2009, 182 ICSI cycles were performed where oocyte vitrification was possible. A total of 104 first and 11 second oocyte warming cycles were then performed in non-pregnant patients of the same cohort. The overall ongoing pregnancy rates obtained in the fresh, and first and second warming cycles were 37.4, 25.0 and 27.3%, respectively. The overall cumulative ongoing clinical pregnancy rate observed per stimulation cycle was 53.3%. Maternal age was the only characteristic found to influence the reproductive outcome, with an inverse correlation between the age >40 and the ongoing pregnancy rates (P = 0.04, by Cox regression analysis).CONCLUSIONSHigh cumulative ongoing pregnancy rates can be obtained with transfers of embryos derived from fresh and cryopreserved oocytes in a typical infertile population. Female age significantly affects outcomes in this system.
In patients with non-obstructive azoospermia, testicular sperm extraction (TESE) is a method of choice to recover spermatozoa as a male therapeutic approach in intracytoplasmic sperm injection (ICSI) programmes. However, the efficacy of TESE in this indication is burdened by a frequent failure of sperm recovery, which renders useless both the invasive testicular intervention and ovarian stimulation of the patient's spouse. One of the most frequent pathological pictures characterizing complete absence of spermatozoa is germinal aplasia (Sertoli cell- only syndrome or SCOS). Two different histological patterns of SCOS have been already described during the past five decades. These two patterns can be characterized as the congenital (pure) and the secondary (mixed) forms. Both patterns, with different prognosis to retrieve spermatozoa by therapeutic testicular biopsy, are frequently confused when TESE is performed during ICSI programmes. Useful criteria to predict the absence of spermatozoa can be obtained by a definite recognition of the two typical histological patterns during the diagnostic testicular biopsy. The diagnosis of congenital or acquired SCOS can be refined by endocrine, chemical, immunohistochemical and molecular biology aids. Reduction of both sperm retrieval failure and unnecessary ovarian stimulation can be achieved by combination of these methods.
Controversial reports have been published about the influence of sperm source and of the underlying testicular pathology on success rates of intracytoplasmic sperm injection (ICSI). In this controlled study, ICSI treatment cycles with testicular spermatozoa from men with obstructive and non-obstructive azoospermia were compared with ICSI ejaculated sperm cycles with semen parameters < or = 5 x 10(6)/ml and < or = 10% progressive motility. The control cases were matched for female age, rank of trial, female basal follicle-stimulating hormone serum concentrations and close proximity to the study group's procedure. The fertilization, cleavage, pregnancy and abortion rates were similar in matched groups irrespective of the type of azoospermia. However, the implantation rate in the non-obstructive azoospermic patient group was significantly lower than that in the matched ejaculated sperm group (13.4% versus 26%, P = 0.05). On the other hand, no impairment of the implantation rate was observed in the obstructive azoospermic patient group. These data show that testicular pathology has a negative impact on reproductive performance of testicular spermatozoa, resulting in a decreased implantation potential without any apparent effect on fertilization and early preimplantation development.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.